Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ORKANASDAQ:PGENNASDAQ:RAPPOTCMKTS:TBUFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeORKAOruka Therapeutics$12.44+5.4%$11.08$5.49▼$31.13$465.38M-0.34234,808 shs28,031 shsPGENPrecigen$1.65+13.4%$1.44$0.65▼$2.17$485.57M1.781.41 million shs1.72 million shsRAPPRapport Therapeutics$11.87+4.9%$10.96$6.43▼$29.74$432.56MN/A164,729 shs7,304 shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceORKAOruka Therapeutics+5.26%+0.34%+6.88%+25.27%+1,179,999,900.00%PGENPrecigen+2.11%-3.33%+9.85%-2.03%-6.45%RAPPRapport Therapeutics-0.53%-8.64%+34.64%+13.55%+1,130,999,900.00%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationORKAOruka Therapeutics3.0293 of 5 stars3.60.00.00.03.32.50.6PGENPrecigen3.9929 of 5 stars3.51.00.04.72.21.70.6RAPPRapport Therapeutics2.287 of 5 stars3.50.00.00.03.80.00.6TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceORKAOruka Therapeutics 3.20Buy$40.38224.69% UpsidePGENPrecigen 3.00Buy$6.00264.74% UpsideRAPPRapport Therapeutics 3.00Buy$28.00135.99% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBUFF, RAPP, PGEN, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/APGENPrecigen$3.92M123.87N/AN/A$0.13 per share12.65RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%7/30/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TBUFF, RAPP, PGEN, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthORKAOruka TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioORKAOruka TherapeuticsN/A30.0330.03PGENPrecigenN/A3.533.53RAPPRapport TherapeuticsN/A31.0131.01TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipORKAOruka Therapeutics56.44%PGENPrecigen33.51%RAPPRapport TherapeuticsN/ATBUFFTribute Pharmaceuticals CanadaN/AInsider OwnershipCompanyInsider OwnershipORKAOruka Therapeutics24.69%PGENPrecigen47.10%RAPPRapport TherapeuticsN/ATBUFFTribute Pharmaceuticals CanadaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableORKAOruka TherapeuticsN/A37.44 million28.20 millionN/APGENPrecigen190295.18 million156.15 millionOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ATBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTBUFF, RAPP, PGEN, and ORKA HeadlinesRecent News About These CompaniesSimone Biles pays tribute to husband Jonathan Owens with tiny new tattooSeptember 21, 2024 | pagesix.comPKid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?September 14, 2024 | snopes.comSTRANSFORMERS ONE - Advance Screening & Prize Pack ContestSeptember 12, 2024 | tribute.caTCate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”September 11, 2024 | deadline.comDInside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar SnubsSeptember 11, 2024 | variety.comVTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comTop country stars honor Toby Keith in a new special. Here's how to watchSeptember 1, 2024 | today.comT‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tributeJuly 31, 2024 | pagesix.comPValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comAbout Tribute.caApril 1, 2024 | tribute.caTMacGregor: A Remembrance Day tribute to Canada's Korean War veteransNovember 13, 2023 | ottawacitizen.comOChurch Under Fire: Canada's War on Christianity - CastOctober 25, 2023 | tribute.caTTerry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore iconAugust 27, 2023 | sportingnews.comSRon Canada Biography & MoviesJuly 23, 2023 | tribute.caTWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comAlberta tattoo artists pay tribute to laser removal expert who helped people move past traumaApril 29, 2023 | cbc.caMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comHumboldt holds tribute five years after deadly bus crashApril 8, 2023 | thestar.comTPaul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock deathApril 3, 2023 | thesun.co.ukGamer Crochets Destiny 2 Tribute to Zavalla Actor Lance ReddickApril 3, 2023 | gamerant.comGNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, RAPP, PGEN, and ORKA Company DescriptionsOruka Therapeutics NASDAQ:ORKA$12.44 +0.64 (+5.38%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Precigen NASDAQ:PGEN$1.64 +0.20 (+13.45%) As of 11:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Rapport Therapeutics NASDAQ:RAPP$11.86 +0.56 (+4.91%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
